Cell Responses to IFN-gamma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01317017
Recruitment Status : Terminated (Unable to isolate sufficient cells from the skin biopsy to perform study experiments.)
First Posted : March 16, 2011
Last Update Posted : March 5, 2013
Information provided by (Responsible Party):
Rockefeller University

Brief Summary:
IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Drug: Actimmune Early Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients
Study Start Date : July 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources

Intervention Details:
    Drug: Actimmune
    • All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.
    • Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.
    • Patients will return at one to two weeks for suture removal.
    • Clinical assessments done at every visit.
    • Patients will also be evaluated at each visit for any adverse events.

Primary Outcome Measures :
  1. Function of dendritic cells from IFNg-injected skin [ Time Frame: 6 months ]
    To perform an assay using dendritic cells from the biopsy as stimulator cells and T cells as responders.

Secondary Outcome Measures :
  1. Flow cytometry analysis of circulating leukocyte populations [ Time Frame: 9 months ]
    Surface phenotype and intracellular cytokine staining will be performed to determine if a single dose of IFNg alters circulating leukocyte phenotype.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent
  • Normal volunteers with no evidence of skin disease OR diagnosis of plaque type psoriasis for at least 6 months
  • 18 years of age or greater
  • For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study. Acceptable methods of contraception include use of a condom; abstinence; use by sexual partner of oral implantable or injectable contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap; or a sterile sexual partner

Exclusion Criteria:

  • Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
  • Clinically significant psoriasis flare during screening or on the first treatment day
  • Hypersensitivity to IFN-g or E. coli derivatives
  • Pre-existing, uncontrolled myelosuppression, cardiac disease, seizure disorders, compromised central nervous system function or multiple sclerosis
  • History of malignancy, clinically significant renal insufficiency, poorly controlled medical conditions that would increase the risks
  • Presence of malignancy within the past 5 years, including lymphoproliferative disorders. Subjects with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
  • Pregnancy or lactation. As the risk of IFN-g in pregnancy is unknown, pregnant women will be excluded from the study.
  • Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01317017

United States, New York
Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Rockefeller University
Principal Investigator: Michelle Lowes, MD The Rockefeller University

Responsible Party: Rockefeller University Identifier: NCT01317017     History of Changes
Other Study ID Numbers: MLO-0717
First Posted: March 16, 2011    Key Record Dates
Last Update Posted: March 5, 2013
Last Verified: March 2013

Keywords provided by Rockefeller University:

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Antiviral Agents
Anti-Infective Agents